{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:48:43Z","timestamp":1791301723326,"version":"4.1.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The efficacy and safety of chimeric antigen receptor T (CAR-T) cell therapy in the treatment of non-Hodgkin\u2019s lymphoma has already been demonstrated. However, patients with a history of\/active secondary central nervous system (CNS) lymphoma were excluded from the licensing trials conducted on two widely used CAR-T cell products, Axicabtagene ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel). Hence, the objective of the present review was to assess whether secondary CNS lymphoma patients would derive a benefit from Axi-cel or Tisa-cel therapy, while maintaining controllable safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Two reviewers searched PubMed, Embase, Web of Science, and Cochrane library independently in order to identify all records associated with Axi-cel and Tisa-cel published prior to February 15, 2021. Studies that included secondary CNS lymphoma patients treated with Axi-cel and Tisa-cel and reported or could be inferred efficacy and safety endpoints of secondary CNS lymphoma patients were included. A tool designed specifically to evaluate the risk of bias in case series and reports and the ROBINS-I tool applied for cohort studies were used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten studies involving forty-four patients were included. Of these, seven were case reports or series. The other three reports were cohort studies involving twenty-five patients. Current evidence indicates that secondary CNS lymphoma patients could achieve long-term remission following Axi-cel and Tisa-cel treatment. Compared with the non-CNS cohort, however, progression-free survival and overall survival tended to be shorter. This was possibly due to the relatively small size of the CNS cohort. The incidence and grades of adverse effects in secondary CNS lymphoma patients resembled those in the non-CNS cohort. No incidences of CAR-T cell-related deaths were reported. Nevertheless, the small sample size introduced a high risk of bias and prevented the identification of specific patients who could benefit more from CAR-T cell therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Secondary CNS lymphoma patients could seem to benefit from both Axi-cel and Tisa-cel treatment, with controllable risks. Thus, CAR-T cell therapy has potential as a candidate treatment for lymphoma patients with CNS involvement. Further prospective studies with larger samples and longer follow-up periods are warranted and\u00a0recommended.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.693200","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T07:59:03Z","timestamp":1625471943000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review"],"prefix":"10.3389","volume":"12","author":[{"given":"XiaoQin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XinYue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RenDe","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MengSi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JianChao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8021","article-title":"Natural History of Cns Relapse in Patients With Aggressive non-Hodgkin\u2019s Lymphoma: A 20-Year Follow-Up Analysis of Swog 8516-the Southwest Oncology Group","volume":"27","author":"Bernstein","year":"2009","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl327","article-title":"Incidence and Risk Factors of Central Nervous System Recurrence in Aggressive Lymphoma -\u00a0A Survey of 1693 Patients Treated in Protocols of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL)","volume":"18","author":"Boehme","year":"2007","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm073","article-title":"Central Nervous System Occurrence in Elderly Patients With Aggressive Lymphoma and a Long-Term Follow-Up","volume":"18","author":"Bj\u00f6rkholm","year":"2007","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.02.009","article-title":"Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-Dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen","volume":"20","author":"Young","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14187","article-title":"High-Dose Therapy and Autologous Stem Cell Transplantation may Only be Applicable to Selected Patients With Secondary CNS Diffuse Large B-Cell Lymphoma","volume":"178","author":"Cheah","year":"2017","journal-title":"Br\u00a0J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.1236","article-title":"High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial","volume":"33","author":"Ferreri","year":"2015","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.077917","article-title":"Phase II Study of Central Nervous System (CNS)-Directed Chemotherapy Including High-Dose Chemotherapy With Autologous Stem Cell Transplantation for CNS Relapse of Aggressive Lymphomas","volume":"98","author":"Korfel","year":"2013","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29023","article-title":"Phase 2 Trial of High-Dose Rituximab With High-Dose Cytarabine Mobilization Therapy and High-Dose Thiotepa, Busulfan, and Cyclophosphamide Autologous Stem Cell Transplantation in Patients With Central Nervous System Involvement by non-Hodgkin Lymphoma","volume":"121","author":"Chen","year":"2015","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.811239","article-title":"Impact of Rituximab on Incidence of and Risk Factors for Central Nervous System Relapse in Patients With Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis","volume":"55","author":"Zhang","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1\u20132 Trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25951","article-title":"Commercial Anti-CD19 CAR T Cell Therapy for Patients With Relapsed\/Refractory Aggressive B Cell Lymphoma in a European Center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-Of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124750","article-title":"Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (Us)","volume":"134","author":"Pasquini","year":"2019","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130983","article-title":"Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults With Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience From the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry","volume":"134","author":"Jaglowski","year":"2019","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric Antigen Receptor T-Cell Therapy-Assessment and Management of Toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated With Car T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discovery"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood\u2013Brain Barrier Disruption in Neurotoxicity After Adoptive Immunotherapy With CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B23","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical Presentation, Management, and Biomarkers of Neurotoxicity After Adoptive Immunotherapy With CAR T Cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-Derived IL-1 and IL-6 are Differentially Required for Cytokine-Release Syndrome and Neurotoxicity Due to CAR T Cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults With Chemotherapy-Refractory Acute Lymphoblastic Leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection During the First Year in Patients Treated With CD19 CAR T Cells for Diffuse Large B Cell Lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological Quality and Synthesis of Case Series and Case Reports","volume":"23","author":"Murad","year":"2018","journal-title":"Evid Based Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A Tool for Assessing Risk of Bias in non-Randomised Studies of Interventions","volume":"40","author":"Hinneburg","year":"2017","journal-title":"Med Monatsschr Pharm"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129097","article-title":"Experience With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Secondary CNS Involvement: Results From the US Lymphoma CAR T Consortium","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0476-y","article-title":"Safety and Feasibility of Chimeric Antigen Receptor T Cell Therapy After Allogeneic Hematopoietic Cell Transplantation in Relapsed\/Refractory B Cell Non-Hodgkin Lymphoma","volume":"33","author":"Jain","year":"2019","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene Ciloleucel CD19 CAR-T Cell Therapy Results in High Rates of Systemic and Neurologic Remissions in Ten Patients With Refractory Large B Cell Lymphoma Including Two With HIV and Viral Hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune Effector Cell-Associated Neurotoxicity Syndrome After Chimeric Antigen Receptor T-Cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes","volume":"23","author":"Holtzman","year":"2021","journal-title":"Neuro Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and Radiologic Correlates of Neurotoxicity After Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01099-4","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy for Relapsed\/Refractory Secondary CNS non-Hodgkin Lymphoma: Comparable Outcomes and Toxicities, But Shorter Remissions may Warrant Alternative Consolidative Strategies","volume":"56","author":"Ghafouri","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.09.006","article-title":"Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement","volume":"94","author":"Novo","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B40","doi-asserted-by":"crossref","first-page":"P3.6-009","DOI":"10.1212\/WNL.92.15_supplement.P3.6-009","article-title":"Ischemic Stroke After CAR-T Cell Therapy","volume":"92","author":"Shah","year":"2019","journal-title":"Neurology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001694","article-title":"Al Et. Tisagenlecleucel CAR T-Cell Therapy in Secondary CNS Lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20411","article-title":"CART Cell Infusion Following Checkpoint Inhibition can Induce Remission in Chemorefractory Post-Transplant Lymphoproliferative Disease (PTLD) of the Central Nervous System","volume":"150","author":"R\u00f6sler","year":"2020","journal-title":"Swiss Med Wkly"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical Activity of Axicabtagene Ciloleucel in Adult Patients With Richter Syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-Cell Toxicity Grading Systems: Application of the ASTCT Grading System and Implications for Management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies can be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1215134","article-title":"Chimeric Antigen Receptor\u2013Modified T Cells for Acute Lymphoid Leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.11.004","article-title":"Determinants of Response and Resistance to CAR T Cell Therapy","volume":"65","author":"Lesch","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884","article-title":"Targeting B Cell Receptor Signaling With Ibrutinib in Diffuse Large B Cell Lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e595-7","DOI":"10.1200\/JCO.2011.34.7252","article-title":"Regression of Refractory Intraocular Large B-Cell Lymphoma With Lenalidomide Monotherapy","volume":"29","author":"Rubenstein","year":"2011","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126253","article-title":"Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients","volume":"134","author":"Sterling","year":"2019","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed\/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion From the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and Managing Large B Cell Lymphoma Relapses After Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Byrne","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.693200\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T09:34:46Z","timestamp":1725356086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.693200\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2021.693200"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.693200","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"article-number":"693200"}}